Kornimate/medical-research-clean huggingface dataset:
a multicenter, randomized, parallel group, double-blind, placebo controlled, flexible dose escalation study to evaluate sexual and relationship satisfaction in the female partner of men with erectile dysfunction treated with sildenafil citrate

Conditions: Erectile Dysfunction

Summary: to compare the effects of sildenafil versus placebo on the female partner's sexual satisfaction as assessed by question 3 of female partner of erectile dysfunction (ed) subject questionnaire (fepeds-q): "over the past 4 weeks, when you had sexual intercourse, how often was it satisfactory for you?" for ed subjects, determine difference in the erectile function domain of international index of erectile function (iief) between sildenafil citrate and placebo at end of the treatment phase and determine the overall relationship between improved erectile function and increased ed subject and female partner satisfaction.


Eligibility criteria:
inclusion criteria: * the male patient must have had a documented clinical diagnosis of erectile dysfunction (ed) confirmed by a sexual health inventory-male (shi-m) score of less than or equal to 21 * a stable female partner at least 21 years of age for at least 6 months prior to screening * the couple must have been married or living together at the time of screening. * the female partner must have answered "no intercourse," "sometimes," "a few times" or "almost never" on question 3 of the female partner of ed subject questionnaire (fepeds-q) exclusion criteria: * the male patient must not have had resting sitting and/or standing hypotension (bp \ 170/110mmhg), or significant cardiovascular disease in the last 3 months, including cardiac failure, myocardial infarction, unstable angina, stroke, transient ischemic attack (tia), symptomatic or clinically significant cardiac arrhythmias. * female partners must not have had significant dyspareunia or lifelong significant sexual dysfunction based on female partner's medical and sexual history at screening.
hearing resources and outcomes in the emergency department (hero-ed)

Conditions: Hearing Loss

Summary: the hearing resources and outcomes in the emergency department pilot (hero-ed pilot), gathers preliminary data and hones procedures and measures, prior to undertaking hero-ed. since the hero-ed pilot does not involve random assignment (no control group), it will not test device effectiveness. however, the hero-ed pilot will test device acceptability and use. it will also provide preliminary data on, and allow us to fine-tune, the measures of effectiveness that we plan to use in hero-ed

the objectives are: 1. measure the feasibility of in-ed hearing screening using hhie-s and a handheld audiometer, among low-acuity11 ed patients age ≥75 years, by quantifying the proportion of eligible patients who complete hearing screening. 2. test whether low-acuity older ed patients who screen positive for significant hearing loss (\> 40 db hl bilaterally and hhie-s \> 24) and are provided a hearing assistance device (had) use that device during the ed visit. 3. test whether patients who are given a hearing assistance device will report ability as opposed to disability in hearing and understanding, using a six-item questionnaire adapted from a study by cox et al. 4. test whether those who are given a hearing assistance device will report being prepared for post-discharge care, using an adapted subset of the care transitions measures (ctm). 5. assess patient understanding of the had survey items within the post-use survey.

Eligibility criteria:
inclusion criteria: * low acuity clinical presentation (emergency severity index11 triage criteria of 4 or 5, which indicates a high likelihood of being discharged home from the emergency department). * patients using hearing aids will not be excluded. exclusion criteria: * lack of capacity to consent, as defined by the patient's ability to satisfactorily answer the questions outlined in the evaluation to sign consent form (esc) mentioned in the protocol. a legal representative/family member will not be able to consent for the patient in this study.
safety and efficacy of using hdh device and method - a novel sutureless vascular anastomosis

Conditions: Vascular Disease; Atherosclerosis

Summary: the hdh device is intended for creating sutureless vascular anastomosis in various blood vessels. the hdh device consists of four parts: an elastic tube (graft), docking head (anastomotic device), inversion device (connects the vascular graft to hdh) and measuring device. this study was design in order to evaluate the safety and efficacy of using hdh device and method an innovative anastomotic device for sutureless aortic anastomosis in patient diagnosed with abdominal aneurysm or aorto-iliac aneurysm.


Eligibility criteria:
inclusion criteria: * patient age above 18 (men and woman) * patient suffers from infrarenal abdominal aortic or aorto-iliac aneurysm * aneurysm diameter is larger than 5cm/ its annual growth is more than 0.5cm/or iliac aneurysm size is larger than 2.5cm * the abdominal aneurysm neck is longer than 1.5 cm * patient's physical condition allows performing general anesthesia * patient is willing to sign the informed consent and follow the study protocol. exclusion criteria: * patient age under 18 years * patient's physical condition dose not allows to perform general anesthesia * patient's with terminal disease and life expectancy of less than 3 months * patient objects to the treatment or study protocol * anesthesiologist or personal care physician object * patient suffer from supra/infrarenal aaa * the abdominal aneurysm neck is smaller than 1.5 cm * aneurysm diameter is smaller than 5cm/ its annual growth is less than 0.5cm/

Keywords: sutureless vascular bypass
a functional outcomes study with atomoxetine-hydrochloride and placebo in adults with attention-deficit/hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the overall primary objective of this study is to test the hypothesis that, compared with placebo,administration of atomoxetine will result in an improved work productivity.


Eligibility criteria:
inclusion criteria: 1. meet dsm-iv criteria for attention-deficit/hyperactivity disorder (adhd). 2. have a cgi-s-adhd score of 4 (moderate symptoms) or greater at visit 1 and visit 2. 3. adult men or women, 18 years of age or older and not more than 50 years of age at visit 1. 4. laboratory results must show no clinically significant abnormalities. 5. paid employees working 20 hours or more per week and who have been paid in their current place of employment for 6 months or more. exclusion criteria: 1. meet diagnostic criteria for current major depression, a current anxiety disorder and history of bipolar disorder or any history of a psychotic disorder will be excluded from the study. 2. are pregnant or are breastfeeding. 3. have organic brain disease. have a history of any seizure disorder or patients who have taken or are currently taking anticonvulsants for seizure control. 4. are taking any psychotropic medication on a regular basis that has central nervous system activity. must have a washout equal to a minimum of 5 half-lives of that medication prior to visit 2. 5. are unstable in any way to participate in this study, in the opinion of the investigator.
effects of using custom photobiomodulation therapy for the treatment of osteoarthritis of the fingers and rhizarthrosis

Conditions: Osteoarthritis; Osteoarthritis Finger; Osteoarthritis Hand; Osteoarthritis Both Hands

Summary: osteoarthrosis (oa), a multifactorial degenerative process, is responsible for joint pain and functional limitation. in the hand, more specifically in the proximal and distal interphalangeal joints of the fingers, it is one of the sites of greatest manifestation of the disease. numerous treatments, whether drug, rehabilitation or surgery, have been proposed with the aim of both interrupting the natural evolution of the disease and alleviating or stopping the symptoms. this study aims to evaluate the effectiveness of personalized photobiomodulation therapy (pbt) with regard to alleviating symptoms and improving the quality of life of these patients with the disease.


Eligibility criteria:
inclusion criteria: * clinical and radiological diagnosis of oa of the fingers of the hand and rizarthrosis * patients with pain for at least 3 months * patients undergoing treatment and rehabilitation for finger oa and rhizarthrosis * patient with good understanding of the portuguese language who agrees to participate and sign the icf exclusion criteria: * posttraumatic arthritic changes * systemic inflammatory arthritis (rheumatoid arthritis, lupus erythematosus, psoriasis...) * patients with local or systemic, acute or chronic infections
the purpose of this study is to determine the frequency of colorectal cancer in male and female endurance athletes between the ages of 35 and 50

Conditions: Colorectal Cancer

Summary: the purpose of this study is to determine the frequency of colorectal cancer in male and female endurance athletes between the ages of 35 and 50.


Eligibility criteria:
inclusion criteria: * adult males and females 35-50 years of age * male and female self-reported endurance athletes, defined by at least one of the following: * run at least two races of 50 miles or more * run 5 races of 26.2 miles or more * ability to complete testing in the protocol and make study visits * able and willing to consent to protocol exclusion criteria: * known or suspected history of inflammatory bowel disease, familial adenomatous polyposis (fap), or lynch syndrome * concomitant illness that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants. * anticipated poor compliance * prisoners or subjects who are involuntarily incarcerated * persons with decisional incapacity/cognitive impairment * any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study * subject is involved with a worker's compensation, personal injury, or other legal matters related to their health * subject is enrolled in a separate interventional clinical trial
characteristics of marrow fatty cells in the ageing of bone and joints, osteoarthritis and osteoporosis

Conditions: Osteoarthritis, Knee; Prosthesis User

Summary: obesity and other associated complications promote the development and the progression of osteoarthritis. the subcutaneous and abdominal fat release several factors that alter bone and the cartilage. the role of the marrow fat in close connection with bone has not been defined yet, whereas cellular and animal models indicate that this fat depot modifies bone and cartilage. the aim of the study is to define if the marrow fat produces more joint-altering factors by comparison with subcutaneous fat. this fat depot can be characterized from removed pieces during the prosthetic surgery of the knee. measuring before surgery the body weight, waist and hip circumferences, blood pressure, glucose, insulin and lipids in blood will also allow to determine if obesity and/or type 2 diabetes make this fat more dangerous for the joint. such research will allow the elaboration of new therapeutic strategies in osteoarthritis.


Eligibility criteria:
inclusion criteria: * post-menopausal woman * with a symptomatic knee osteoarthritis requiring prosthesis * able to handle general anaesthesia * having given her consent * able to understand the constraints associated with the study * with health insurance * able to understand the french language exclusion criteria: * with refusal to participate to the study * more than 85-year-old * with bone pathologies other than osteoarthritis or osteoporosis * with active infection * with evolving cancer * with haematopoietic pathologies such as haemoglobin pathologies * with thyroid pathologies * with type 1 diabetes * with anti-osteoporotic treatments (bisphosphonates, strontium ranelate, teriparatide, denosumab) except calcium and vitamin d supplementation or hormone replacement. * with replacement of prosthesis * with previous surgery at the surgery site --with a current participation to another study * with guardianship * with deprived liberty

Keywords: osteoarthritis prosthetic surgery of the knee obesity type 2 diabetes bone marrow fat
end-of-life decision-making among young patients with advanced cancer: a grounded theory approach

Conditions: End-of-life Decision-making

Summary: the purpose of this qualitative research is to use grounded theory to explore and describe the thoughts of young advanced cancer patients regarding end-of-life care and how these thoughts influence the related decision-making process.


Eligibility criteria:
inclusion criteria: * the patient has a solid tumor. * the age at initial cancer diagnosis is between 15 and 39 years. * the patient is at least 18 years old at the time of enrollment. * the patient has cancer with metastasis, either present at initial diagnosis or occurring after treatment or follow-up. * after metastasis, the first-line curative treatment is ineffective. exclusion criteria: - patients who, for any reason, including severe psychological distress (as determined by the attending physician, psychiatrist, or specialist nurse based on assessments and impressions during routine patient care), cognitive impairment, or physical limitations (such as frailty), are unable to communicate or participate in an interview lasting more than 30 minutes.

Keywords: young patients advanced cancer grounded theory
unravelling the measles paradox in children

Conditions: MEASLES DISEASE

Summary: measles is caused by measles virus (mev). the disease is associated with lymphopenia and immune suppression, which is an important cause of measles-associated morbidity and mortality. measles-induced immune suppression can last several years, whereas measles lymphopenia is usually resolved within two weeks. at the same time, measles induces lifelong immunity. this apparent contradiction, known as the 'measles paradox', was partially solved when investigators demonstrated that mev infects and depletes pre-existing memory cells, thereby causing 'immune amnesia'. this model is supported by observations in animal models and clinical studies, but several questions remain to be addressed, like the duration of measles-induced amnesia and changes in the immune repertoire after measles. to address the immunological questions regarding mev infection.

measles is caused by measles virus (mev). the disease is associated with lymphopenia and immune suppression, which is an important cause of measles-associated morbidity and mortality. measles-induced immune suppression can last several years, whereas measles lymphopenia is usually resolved within two weeks. at the same time, measles induces lifelong immunity. this apparent contradiction, known as the 'measles paradox', was partially solved when investigators demonstrated that mev infects and depletes pre-existing memory cells, thereby causing 'immune amnesia'. this model is supported by observations in animal models and clinical studies, but several questions remain to be addressed, like the duration of measles-induced amnesia and changes in the immune repertoire after measles. recently, investigators have acquired permission to address these remaining questions in 18-25 years old adults (mec-2024-0230). however, investigators have reservations about the feasibility of including enough participants between 18 and 25 years old that have not been vaccinated against or infected with mev; it is possible that investigators will not reach sufficient inclusions to address the immunological questions regarding mev infection in that protocol. therefore, investigators propose to additionally study these questions in children in the age of 4 up to and including 17.

Eligibility criteria:
inclusion criteria: group a * aged 4 - 17 years old * susceptible to measles * no pre-existing immunity against measles (vaccination or earlier infection) group b * aged 4 - 17 years old * protected against measles due to vaccination or earlier infection exclusion criteria: a potential subject who meets any of the following criteria will be excluded from participation in this study: * diagnosed chronic disease that lasted over 3 months * immune suppression (due to medication or underlying disease) * group a; detectable mev-antibodies in the t1 blood sample

Keywords: measles immune response
risk prediction of taxane chemotherapy-induced peripheral neuropathy

Conditions: Breast Cancer; Chemotherapy-induced Peripheral Neuropathy; Aging

Summary: this is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (cipn) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (university of north carolina at chapel hill (unc) hospital, including rex hospital, and the university of alabama at birmingham (uab) hospital). the primary purpose of this study to explore patient- and procedure-based variables that identify patients at risk for developing cipn during chemotherapy.

chemotherapy-induced peripheral neuropathy is common and provokes pain, poor qol, and loss of independence, as well as increases the risk of falls and opioid addiction. beyond the inciting agents, risk factors for cipn are not understood or systematically evaluated in clinical practice, precluding prevention. therefore, a clinical decision tool to predict an individual patient's risk of neuropathy remains a critical unmet need. a diagnostic test that predicts cipn risk in this clinical context would provide an essential clinical-decision tool to guide treatment and post-treatment care in breast cancer, prevent cipn occurrence, and improve patient outcomes. investigators' pilot data uncovered a strong association between cellular senescence and cipn. in this prospective, observational study of participants with early-stage breast cancer, the investigators will assess the contribution of senescence and clinical variables. the investigators will determine the ability of these factors to identify patients at risk for cipn during chemotherapy and up to one year after the last dose of taxane-based chemotherapy. this study will employ both patient- and clinician reported cipn scoring systems.

Eligibility criteria:
inclusion criteria: study participants must meet all of the following inclusion criteria to participate in the study: * adult female study participants (≥18 years) with newly diagnosed early-stage (stages i iii) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel * study participants must be capable and willing to provide informed consent, and be willing and able to complete the study questionnaires during the study exclusion criteria: study participants who fulfill any of the following criteria will be excluded: * patients with metastatic breast cancer * history of other cancers (except squamous and basal cell carcinoma) * autoimmune disorders * presence of major active infection for which antibiotics and/or antivirals are prescribed within the last 14 days (chronic or acute, eg, sepsis, hiv, pneumonia, active covid infection) * pregnant women * participation in an additional study at the time of enrollment where the intervention could potentially alter cipn risk (unless in the control arm)
the effectiveness and the safety of acupuncture for symptomatic care of hemodialysis patients: a case-series

Conditions: Hemodialysis; End Stage Renal Disease

Summary: purpose: hemodialysis-dependent patients with an end-stage renal disease (esrd) suffer from a number of distressing symptoms, such as pain, poor mental health, fatigue, sleep disturbance and pruritus. these negatively influence health-related quality of life in esrd patients, and some of them result in increased mortality and hospitalization. acupuncture is a widely employed treatment on several chronic disease or condition. adjunctive use of acupuncture with conventional treatment could be a possible therapeutic option to establish an optimal care for esrd patients who experiences co-morbid conditions or complications of hemodialysis. due to its non-pharmacologic feature, the effects of acupuncture without involving altered pharmacokinetics and drug-interactions in hemodialysis patients, might be another strong point compared to other pharmacological interventions. however, little information is available for the effects and the safety of acupuncture for symptomatic care of hemodialysis patients. thus, the investigators propose whether acupuncture could be a effective and safe therapeutic modality for a number of patient-reported symptoms in hemodialysis-dependent patients with esrd.

this trial is a case-series, with a nested-qualitative study at the end of follow-up. acupuncture treatment will be provided biweekly for 6 weeks, namely total 12 sessions, and follow-up period will be 4 weeks after the end of treatment. changes of symptoms, quality of life and occured adverse events will be assessed during study procedure. patients who agreed joining qualitative research will be interviewed about their experiences of acupuncture in detail.

Eligibility criteria:
inclusion criteria: * over 19 years old * started hemodialysis at least 3 months ago * receiving hemodialysis 3 times a week regularly * equilibrated kt/v ≥ 1.2 * willingness to participate in this study exclusion criteria: * acute/chronic liver disease * events of life-threatening cardiovascular disease within 6 months * events of life-threatening neurological disorder within 6 months * current/past history of neoplasm * hemorrhagic disorders * drug abuse/alcoholism * other infectious disease including active tuberculosis * history of the use of acupuncture, moxibustion or herbs within 1 month

Keywords: acupuncture hemodialysis symptom end stage renal disease chronic kidney disease supportive care
health and employment after gastro intestinal surgery - heagis2

Conditions: Esophageal Neoplasms; Gastric Neoplasm; Colon Neoplasms

Summary: by using the m.a.d.i.t. methodology and the dialogics science, salvo project aims to develop operational guidelines to support oncological target patients in the resumption of their daily post-operative activities. the research will implement an instrument for the purpose of measuring the health need of participants who are admitted to the surgical ward. therefore, targeted interventions will be implemented with participants, and efficacy will be evaluated in order to define treatment guidelines. the principal aim of this study is to create a validated and replicable intervention model for supporting patients who undergone surgery for esophageal and gastro intestinal cancer.

several studies highlight how patients diagnosed with a digestive tract cancer, experience difficulties in returning to work after treatment, leading to socio-economic spill-over effects. a specific 16 questions questionnaire had been developed for this study, the "health and employment after gastro intestinal surgery dialogical questionnaire" (heads-dq). it investigate peculiar patient competences involved after surgery: future forethought; context evaluation; consequences of own actions forethought; use of available resources, each relevant to four areas: clinical; familiar; working; daily-activities. through this questionnaire participants ability in dealing with after surgery consequences will be evaluated in order to describe their development during the post surgery period.

Eligibility criteria:
inclusion criteria: * \>18 years old; * comprehension of italian language; * esophageal or gastrointestinal cancer diagnosis; * curative surgery; * no metastasis or neoplasm recurrence. exclusion criteria: * \<18 years old; * no comprehension of italian language; * not esophageal or gastrointestinal cancer diagnosis; * palliative surgery; * metastasis or neoplasm recurrence.

Keywords: quality of life employment social activities surgery